BRITISH JOURNAL OF HAEMATOLOGY

Volume 110, Issue 1, July 2000

IMAGES IN HAEMATOLOGY

1 **Increased osteoblastic activity in myelomatosis**
K. F. Wong, C. C. So and J. K. C. Chan

HISTORICAL REVIEW

2 **The story of chronic myeloid leukaemia**
C. G. Geary

ANNOTATION

12 **Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation?**
S. Mackinnon

REVIEWS

18 **Neutrophil production and function in newborn infants**
R. Carr

29 **Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia**
E. J. Estlin, S. P. Lowis and A. G. Hall

41 **The modern management of severe aplastic anaemia**
S. E. Ball

HAEMOPOIESIS

Research papers

54 **Modelling haemopoietic stem cell division by analysis of mutant red cells**
M. Vickers, G. C. Brown, J. B. Cologne and S. Kyoizumi

63 **Stem cell factor and erythropoietin inhibit apoptosis of human erythroid progenitor cells through different signalling pathways**
X. Sui, S. B. Krantz and Z. J. Zhao

71 **Mobilization of CD34$^+$ haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4**
M. Lichterfeld, S. Martin, L. Burkly, R. Haas and R. Kronenwett

ERYTHROCYTES

Research paper

82 **Erythropoietin-induced rheological changes of rat erythrocytes**
M. Bor-Kucukatay, O. Yalcin, H. J. Meiselman and O. K. Baskurt

LEUCOCYTES

Research paper

89 **Fas-mediated apoptosis of peripheral blood mononuclear cells in patients with hepatitis C**
N. Taya, Y. Torimoto, M. Shindo, K. Hirai, C. Hasebe and Y. Kohgo

PLATELETS, HAEMOSTASIS AND THROMBOSIS

Research papers

98 **HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant α2b-interferon therapy**
J. García-Suárez, C. Burgaleta, N. Hernanz, F. Albarran, P. Tobaruela and M. Alvarez-Mon

104 **Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia**
A. Wiestner, S. A. Padosch, N. Ghilardi, J. M. Cesar, J. Odriozola, A. Shapiro and R. C. Skoda

110 **Antithrombotic effect of rutaecarpine, an alkaloid isolated from *Evodia rutaecarpa* on platelet plug formation in *in vivo* experiments**
J. R. Sheu, W. C. Hung, C. H. Wu, Y. M. Lee and M. H. Yen

116 **Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders**
M. K. Jensen, P. de Nully Brown, B. Villadsen Lund, O. J. Nielsen and H. C. Hasselbalch

125 **Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism**
P. de Moerloose, G. Reber, A. Perrier, T. Perneger and H. Bounameaux

130 **Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor κB (NF- κB) and tumour necrosis factor α (TNF-α) production in the THP-1 monocytic cell line**
B. White, M. Schmidt, C. Murphy, W. Livingstone, D. O'Toole, M. Lawler, L. O'Neill, D. Kelleher, H. P. Schwarz and O. P. Smith

Short report

135 **Influence of the −675 4G/5G dimorphism of the plasminogen activator inhibitor 1 promoter on thrombotic risk in patients with factor V Leiden**
J. M. Visanji, J. Seargent, D. Tahri, S. A. Croft, M. Makris, F. E. Preston, I. R. Peake and M. E. Daly

HAEMATOLOGICAL MALIGNANCY

Research papers

139 **Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease**
E. R. Van Wering, B. E. M. Van der Linden-Schrever, T. Szczepański, M. J. Willemse, E. A. Baars, H. M. Van Wijngaarde-Schmitz, W. A. Kamps and J. J. M. Van Dongen

147 **Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: a Nordic series comparing two treatment periods**
E. Forestier, B. Johansson, G. Gustafsson, G. Borgström, G. Kerndrup, J. Johannsson and S. Heim for the Nordic Society of Paediatric Haematology and Oncology (NOPHO) Leukaemia Cytogenetic Study Group

154 **Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis *in vitro* do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia**
C. Wuchter, L. Karawajew, V. Ruppert, M. Schrappe, J. Harbott, R. Ratei, B. Dörken and W-D. Ludwig

161 ***In vitro* inhibition of cytidine triphosphate synthetase activity by cyclopentenyl cytosine in paediatric acute lymphocytic leukaemia**
A. C. Verschuur, A. H. Van Gennip, R. Leen, R. Meinsma, P. A. Voute and A. B. P. Van Kuilenburg

170 **The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity**
J. Braess, S. Voß, G. Jahns-Streubel, C. Schoch, T. Haferlach, W. Kern, S. Keye, E. Schleyer and W. Hiddemann

180 **p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome**
V. Brito-Babapulle, R. Hamoudi, E. Matutes, S. Watson, P. Kaczmarek, H. Maljaie and D. Catovsky

188 ***In vitro* and *in vivo* effects of 2′-deoxycoformycin (Pentostatin) on tumour cells from human $\gamma\delta^+$ T-cell malignancies**
D. Aldinucci, D. Poletto, V. Zagonel, M. Rupolo, M. Degan, P. Nanni, V. Gattei and A. Pinto

197 **Post-transplantation lymphoproliferative disease of natural killer cell lineage: a clinicopathological and molecular analysis**
Y. L. Kwong, C. C. K. Lam and T. M. Chan

203 **T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells**
M. Raitakari, R. D. Brown, D. Sze, E. Yuen, L. Barrow, M. Nelson, B. Pope, W. Esdale, J. Gibson and D. E. Joshua

Short reports

210 **Generation of the *NUP98–HOXD13* fusion transcript by a rare translocation, t(2;11)(q31;p15), in a case of infant leukaemia**
H. Shimada, Y. Arai, S. Sekiguchi, T. Ishii, S. Tanitsu and M. Sasaki

214 **Deletion of the 5′-ABL region: a recurrent anomaly detected by fluorescence *in situ* hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients**
C. Herens, F. Tassin, V. Lemaire, Y. Beguin, E. Collard, S. Lampertz, C. Croisiau, M. Lecomte, B. De Prijk, L. Longreé and L. Koulischer

TRANSPLANTATION

Research paper

217 **Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation**
D. Y. Zang, H. J. Deeg, T. Gooley, J. E. Anderson, C. Anasetti, J. Sanders, D. Myerson, R. Storb and F. Appelbaum

GENERAL HAEMATOLOGY AND TRANSFUSION MEDICINE

Research paper

223 **Anti-HPA-5b-induced neonatal alloimmune thrombocytopenia: antibody titre as a predictor**
H. Ohto, T. Yamaguchi, C. Takeuchi, Y. Tohyama, A. Sato, S. Morita and Collaborative Study Group

Short reports

228 **Transfusion-associated graft vs. host disease in a patient with high-grade B-cell lymphoma. Should cellular products for patients with non-Hodgkin's lymphoma be irradiated?**
K. J. Gelly, R. Kerr, S. Rawlinson, A. Norris and D. T. Bowen

230 **Severe pancytopenia triggered by recombinant hepatitis B vaccine**
J.-F. Viallard, J.-M. Boiron, M. Parrens, J.-F. Moreau, V. Ranchin, J. Reiffers, B. Leng and J.-L. Pellegrin

CORRESPONDENCE

234 **Universal leucodepletion to reduce the risk of transmission of new-variant Creutzfeldt–Jakob disease**
M. Sivakumaran

234 **Complication of rapidly progressive glomerulonephritis in severe congenital neutropenia treated with long-term granulocyte colony-stimulating factor (filgrastim)**
M. Sotomatsu, T. Kanazawa, C. Ogawa, T. Watanabe and A. Morikawa

235 **Decreased cord blood yield in post-term pregnancy: a comparative study**
D. V. Surbek, C. Steinmann, A. Tichelli, A. Wodnar-Filipowicz and W. Holzgreve
237 **Polycythaemia as a complication of transdermal testosterone therapy**
J.-F. Viallard, G. Marit, P. Mercié, B. Leng, J. Reiffers and J. L. Pellegrin
238 ***TEL* and *MN1* fusion in myelodysplastic syndrome: new evidence for a therapy-related event**
L. Vieira, B. Marques, A. P. Ambrósio, M. Chumbo, A. B. Reis, E. C. Júnior and M. G. Boavida
239 **Syndecan-1 (CD138) expression in human non-Hodgkin's lymphomas**
M. Sutcliffe, D. Oscier and D. H. Wright
240 **Controversies surrounding the clonogenic origin of multiple myeloma**
F. E. Davies, A. C. Rawstron, R. G. Owen and G. J. Morgan
241 **Translocation t(6;14)(p12;q32): a novel cytogenetic abnormality in splenic lymphoma with villous lymphocytes**
F. Solé, B. Espinet, M. Salido, E. Lloveras, C. Fernández, J. C. Cigudosa, A. Asensio, S. Woessner and L. Florensa
244 **BOOK REVIEW**
245 **ERRATUM**
245 **ANNOUNCEMENTS**

Volume 110, Issue 2, August 2000

IMAGES IN HAEMATOLOGY

247 **Detection of translocation (16;16) in acute myeloid leukaemia (AML) patients by fluorescence *in situ* hybridization (FISH) using 16 telomer's probes**
H. Dar, M. Ziv, H. Bar-El, L. Arbov and E. Dan

HISTORICAL REVIEW

248 **History of tissue factor**
E. Bächli

REVIEWS

256 **Leucocyte depletion of the blood supply – how will patients benefit?**
L. M. Williamson
273 **Towards a targeted, risk-based, antifungal strategy in neutropenic patients**
H. G. Prentice, C. C. Kibbler and A. G. Prentice
285 **Can multidrug resistance mechanisms be modified?**
R. J. Arceci

TRANSPLANTATION

292 **Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue**
A. M. Wardley, G. C. Jayson, R. Swindell, G. R. Morgenstern, J. Chang, R. Bloor, C. J. Fraser and J. H. Scarffe
300 **Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study**
D. Capelli, G. Santini, C. De Souza, A. Poloni, G. Marino, M. Montanari, M. Lucesole, M. Brunori, D. Massidda, M. Offidani, P. Leoni and A. Olivieri

308 **No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission**
J.-Y. Cahn, M. Labopin, J. Sierra, D. Blaise, J. Reiffers, A. Ferrant, L. Bergmann, G. Visani, J. Cornelissen, T. De Witte, A. Bosi, F. Frassoni and N.-C. Gorin for the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

315 **Functional analysis of the $CD8^+CD57^+$ cell population in normal healthy individuals and matched unrelated T-cell-depleted bone marrow transplant recipients**
A. W. Rowbottom, R. J. Garland, M. W. Lepper, S. S. Kaneria, N. J. Goulden, A. Oakhill and C. G. Steward

322 **Determination of helper T-cell precursor frequencies against non-haemopoietic cells: comparison of co-stimulation provided by anti-CD28 antibody versus the cellular ligand B7-1**
A. M. C. van Dijk, G. C. de Gast, F. L. Kessler, S. A. E. Stadhouders-Keet, R. A. W. van Lier, L. F. Verdonck and H. G. Otten

327 **Interleukin 6 receptor expression by human cord blood- or peripheral blood-derived primitive haematopoietic progenitors implies acquisition of different functional properties**
J. Minamiguchi, N. Yahata, T. Kimura, H. Fujiki, S. Harada, J. Wang, K. Okuda, H. Kaneko, K. Hodohara, T. Banba, K. Yasukawa, J. H. Ohyashiki, K. Ohyashiki, T. Abe and Y. Sonoda

Short report 339 **Effective treatment of Jo-1-associated polymyositis with T-cell-depleted autologous peripheral blood stem cell transplantation**
F. Baron, C. Ribbens, O. Kaye, G. Fillet, M. Malaise and Y. Beguin

HAEMATOLOGICAL MALIGNANCY

343 **Mapping of leukaemia-associated breakpoints in chromosome band 3q21 using a newly established PAC contig**
R. Wieser, A. Volz, S. Schnittger, U. Jäger, H. Grüner, J. G. Meran, K. Wimmer, A. Ziegler and C. Fonatsch

351 ***In vitro* anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins**
A. Bolognesi, L. Polito, P. L. Tazzari, R. M. Lemoli, C. Lubelli, M. Fogli, L. Boon, M. De Boer and F. Stirpe

362 **Lack of interferon-α-induced tyrosine phosphorylation of Vav proto-oncogene in patients with myelofibrosis with myeloid metaplasia**
A. Micouin, V. Steunou, J. Wietzerbin and M.-C. Martyré

370 **Significance of lung resistance-related protein in the clinical outcome of acute leukaemic patients with reference to P-glycoprotein**
K. Tsuji, T. Motoji, I. Sugawara, H. Shiozaki, Y.-H. Wang, S. Motomura, M. Okada, T. Yasunami, F. Sano, M. Takahashi, H. Kawada, N. Maseki, S. Hoshino, M. Ishida and H. Mizoguchi

379 **Pegylated asparaginase (Oncaspar™) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols**
H.-J. Müller, L. Löning, A. Horn, D. Schwabe, M. Gunkel, M. Schrappe, V. von Schütz, G. Henze, J. C. da Palma, J. Ritter, J. P. V. Pinheiro, M. Winkelhorst and J. Boos

HAEMOPOIESIS

385 **Surface expression of HLA-DM on dendritic cells derived from CD34-positive bone marrow haematopoietic stem cells**
Y. H. Min, S. T. Lee, K. M. Choi, J. S. Hahn and Y. W. Ko

394 **Ferritin expression in maturing normal human erythroid precursors**
B. Vaisman, E. G. Meyron-Holtz, E. Fibach, A. M. Krichevsky and A. M. Konijn

402 **Evidence for two alternatively spliced forms of phospholipase C-β2 in haematopoietic cells**
G. F. Mao, S. P. Kunapuli and A. K. Rao

Short report 409 **Kell is not restricted to the erythropoietic lineage but is also expressed on myeloid progenitor cells**
T. Wagner, A. Berer, G. Lanzer and K. Geissler

ERYTHROCYTES

412 **Effect of nitric oxide and nitric oxide donors on red blood cell oxygen transport**
B. W. Hrinczenko, A. I. Alayash, D. A. Wink, M. T. Gladwin, G. P. Rodgers and A. N. Schechter

Short report 420 **Severe congenital dyserythropoietic anaemia type I: prenatal management, transfusion support and alpha-interferon therapy**
N. Parez, M. Dommergues, V. Zupan, H. Chambost, J. B. Fieschi, J. Delaunay, F. Miélot, E. M. Cramer, J.-P. Dommergues, S. N. Wickramasinghe and G. Tchernia

LEUCOCYTES

424 **Lymphocyte function antigen 1 (LFA-1) mediates early tumour necrosis factor α-induced leucocyte adhesion in venules**
H. Thorlacius, B. Vollmar, Y. Guo, T. W. Mak, M. M. Pfreundschuh, M. D. Menger and R. Schmits

Short reports 430 **An unusual form of persistent polyclonal B lymphocytosis in an infant**
P. Gomez, E. Matutes, J. Sánchez, J. M. Garcia, J. Román, A. Gruszka-Westwood and A. Torres

434 **Restriction of T-cell receptor repertoires in idiopathic $CD4^+$ lymphocytopenia**
S. Signorini, S. Pirovano, S. Fiorentini, R. Stellini, V. Bianchi, A. Albertini and L. Imberti

438 **Hereditary cyclic neutropenia in the male members of a Chinese family with inverted Y chromosome**
H.-W. Peng, C.-F. Chou and D.-C. Liang

PLATELETS, HAEMOSTASIS AND THROMBOSIS

441 **Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia**
S. van den Oudenrijn, M. Bruin, C. C. Folman, M. Peters, L. B. Faulkner, M. de Haas and A. E. G. Kr. von dem Borne

449 **Dose–response relationship of megakaryocyte progenitors from the bone marrow of thrombocytopenic and non-thrombocytopenic neonates to recombinant thrombopoietin**
M. C. Sola, Y. Du, A. D. Hutson and R. D. Christensen

454 **Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis**
A. D. Mumford, J. O'Donnell, J. D. Gillmore, R. A. Manning, P. N. Hawkins and M. Laffan

461 **Central venous access devices in children with congenital coagulation disorders: complications and long-term outcome**
C. McMahon, J. Smith, K. Khair, R. Liesner, I. M. Hann and O. P. Smith

Short report 469 **The 4G/4G genotype at nucleotide position −675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls**
G. Endler, W. Lalouschek, M. Exner, G. Mitterbauer, D. Häring and C. Mannhalter

TRANSFUSION MEDICINE

472 **Different levels of prion protein (PrPc) expression on hamster, mouse and human blood cells**
K. Holada and J. G. Vostal

481 **Monoclonal antibody-mediated inhibition of the human HLA alloimmune response to platelet transfusion is antigen specific and independent of Fcγ receptor-mediated immune suppression**
A. R. Crow, J. Freedman, B. Hannach and A.H. Lazarus

GENERAL HAEMATOLOGY

488 **Withdrawal of enzyme replacement therapy in Gaucher's disease**
D. Elstein, A. Abrahamov, I. Hadas-Halpern and A. Zimran

CORRESPONDENCE

493 **A thymine base is missed out of the published nucleotide sequence data of the anti-thrombin gene**
T. Ozawa and N. Sakuragawa

493 **The e19a2 bcr/abl breakpoint in acute lymphoblastic leukaemia**
B. Rotoli, F. Pane, F. Salvatore and G. Saglio

496 **Plasma levels of vascular endothelial growth factor (VEGF) in haematological cancers**
F. M. Belgore, G. Y. H. Lip, D. Bareford and A. D. Blann

497 **Hepatitis C virus infection associated with B-cell non-Hodgkin's lymphoma in Hungarian patients**
B. Gasztonyi, A. Pár, Á. Szomor, I. Battyány, Á. Nagy, L. Kereskai, H. Losonczy and G. Mózsik

498 **Compound heterozygosity for triplicated α-globin gene and (——^{SEA}) α-globin gene deletion: implication for thalassaemia screening**
S. K. Ma, A. Y. Y. Chan, L. C. Chan, D. H. K. Chui and J. S. Waye

500 **BOOK REVIEWS**

Volume 110, Number 3, September-I 2000

IMAGES IN HAEMATOLOGY

503 **Angiosarcoma presenting with leucoerythroblastic anaemia bone marrow fibrosis and massive splenomegaly**
N. Varma, K.Vaiphei and S. Varma

HISTORICAL REVIEW

504 **Historical review of Hodgkin's disease**
G. Bonadonna

REVIEW

512 **The management of neoplastic disorders of haematopoiesis in children with Down's Syndrome**
B. Lange

HAEMATOLOGICAL MALIGNANCY

Research papers

525 **Natural killer-type receptors for HLA class I antigens are clonally expressed in lymphoproliferative disorders of natural killer and T-cell type**
T. Hoffmann, G. de Libero, M. Colonna, A. Wodnar-Filipowicz, J. Passweg, G. Favre, A. Gratwohl and A. Tichelli

537 **Variant translocations in sporadic Burkitt's lymphoma detected in fresh tumour material: analysis of three cases**
G. Cario, U. zur Stadt, A. Reiter, K. Welte and K.-W. Sykora

547 **Cytogenetic and molecular evidence of marrow involvement in extramedullary acute myeloid leukaemia**
D. M. Lillington, R. J. Jaju, A. G. Shankar, M. Neat, L. Kearney, B. D. Young and V. Saha

552 **Characterization of apoptosis induced by protein kinase C inhibitors and its modulation by the caspase pathway in acute promyelocytic leukaemia**
H. M. Amin, M. Ergin, M. F. Denning, M. E. Quevedo and S. Alkan

563 **Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia**
R. Möhle, M. Schittenhelm, C. Failenschmid, F. Bautz, K. Kratz-Albers, H. Serve, W. Brugger and L. Kanz

573 **Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials**
Chronic Myeloid Leukaemia Trialists' Collaborative Group

577 **Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial**
G. Finazzi, M. Ruggeri, F. Rodeghiero and T. Barbui

584 **Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes**
K. Shimazaki, K. Ohshima, J. Suzumiya, C. Kawasaki and M. Kikuchi

591 **Expression of the multidrug resistance-associated protein in myelodysplastic syndromes**
S. Poulain, P. Lepelley, C. Preudhomme, N. Cambier, J. Cornillon, E. Wattel, A. Cosson and P. Fenaux

599 **A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations**
S. A. Coulthard, C. Rabello, J. Robson, C. Howell, L. Minto, P. G. Middleton, M. K. Gandhi, G. Jackson, J. McLelland, H. O'Brien, S. Smith, M. M. Reid, A. D. J. Pearson and A. G. Hall

605 **Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization**
S. Schreiber, J. Ackermann, A. Obermair, H. Kaufmann, E. Urbauer, K. Aletaha, H. Gisslinger, A. Chott, H. Huber and J. Drach

Short report

610 **Therapy-related acute myeloid leukaemia after successful therapy for acute promyelocytic leukaemia with t(15;17): a report of two cases and a review of the literature**
S. Zompi, O. Legrand, D. Bouscary, C. M. Blanc, F. Picard, N. Casadevall, F. Dreyfus, J. P. Marie and F. Viguié

TRANSPLANTATION

Research papers

614 **Quality of life in 244 recipients of allogeneic bone marrow transplantation**
S. Chiodi, S. Spinelli, G. Ravera, A. R. Petti, M. T. van Lint, T. Lamparelli, F. Gualandi, D. Occhini, N. Mordini, G. Berisso, S. Bregante, F. Frassoni and A. Bacigalupo

620 **Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)**
T. de Witte, J. Hermans, J. Vossen, A. Bacigalupo, G. Meloni, N. Jacobsen, T. Ruutu, P. Ljungman, A. Gratwohl, V. Runde, D. Niederwieser, A. van Biezen, A. Devergie, J. Cornelissen, J.-P. Jouet, R. Arnold and J. Apperley

631 **A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one half of patients significantly mobilize malignant cells**
C. Jacquy, A. Sorée, F. Lambert, A. Bosly, A. Ferrant, M. André, J. Parma, A. Kentos and P. Martiat

638 **Efficient mobilization of haematopoietic progenitors after a single injection of pegylated recombinant human granulocyte colony-stimulating factor in mouse strains with distinct marrow-cell pool sizes**
G. de Haan, A. Ausema, M. Wilkens, G. Molineux and B. Dontje

647 **Monitoring of residual disease and guided donor leucocyte infusion after allogeneic bone marrow transplantation by chimaerism analysis with short tandem repeats**
R. A. de Weger, M. G. J. Tilanus, K. C. Scheidel, J. G. van den Tweel and L. F. Verdonck

HAEMOPOIESIS

Research papers

654 **High cyclin-dependent kinase inhibitors in Bcl-2 and Bcl-x_L-expressing $CD34^+$-proliferating haematopoietic progenitors**
M. Marone, L. Pierelli, S. Mozzetti, V. Masciullo, G. Bonanno, R. Morosetti, S. Rutella, A. Battaglia, C. Rumi, S. Mancuso, G. Leone, A. Giordano and G. Scambia

663 **Lineage-specific regulation of cell cycle control gene expression during haematopoietic cell differentiation**
Y. Furukawa, J. Kikuchi, M. Nakamura, S. Iwase, H. Yamada and M. Matsuda

674 **A transient assay for regulatory gene function in haemopoietic progenitor cells**
Z. J. McIvor, C. M. Heyworth, B. A. Johnson, S. Pearson, H. Fiegler, L. Hampson, T. M. Dexter and M. A. Cross

682 **Chimaeric mice with disruption of the gene coding for phosphatidylinositol glycan class A (*Pig-a*) were defective in embryogenesis and spermatogenesis**
S.-R. Lin, I.-S. Yu, P.-H. Huang, C.-W. Tsai and S.-W. Lin

ERYTHROCYTES

Short report

694 **α-Thalassaemia as a result of a novel splice donor site mutation of the α_1-globin gene**
C. L. Harteveld, C. Beijer, P. van Delft, R. Zanardini, L. F. Bernini and P. C. Giordano

LEUCOCYTES

Research paper 699 **Quantitative deficiency of monocyte-specific esterase (MSE) mRNA in monocyte esterase deficiency (MED)**
C. Boyle, S. L. Cosby, G. M. Markey, H. D. Alexander and T. C. M. Morris

PLATELETS, HAEMOSTASIS AND THROMBOSIS

Research papers 704 **Platelet ultrastructural abnormalities in three patients with type 2B von Willebrand disease**
P. Nurden, F. Chretien, C. Poujol, J. Winckler, A. Borel-Derlon and A. Nurden

715 **Intermittent injections vs. continuous infusion of Factor VIII in haemophilia patients undergoing major surgery**
A. Batorova and U. Martinowitz

721 **Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII**
D. W. Jones, M. J. Gallimore, I. J. Mackie, S. L. Harris and M. Winter

Short reports 727 **A case of purpura fulminans is caused by homozygous Δ8857 mutation (protein C-Nagoya) and successfully treated with activated protein C concentrate**
T. Nakayama, T. Matsushita, H. Hidano, C. Suzuki, M. Hamaguchi, T. Kojima and H. Saito

731 **Molecular bases of antithrombin deficiency in French families: identification of seven novel mutations in the antithrombin gene**
V. Picard, A. Bura, J. Emmerich, M. Alhenc-Gelas, C. Biron, L. L. Houbouyan-Reveillard, P. Molho, A. Labatide-Alanore, P. Sié, P. Toulon, E. Verdy and M. Aiach

TRANSFUSION MEDICINE

Research paper 735 **Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA-5 alloantigens**
J. E. Berry, C. M. Murphy, G. A. Smith, E. Ranasinghe, R. Finberg, J. Walton, J. Brown, C. Navarrete, P. Metcalfe and W. H. Ouwehand

CORRESPONDENCE

743 **Carcinoembryonic antigen elevation in agnogenic myeloid metaplasia**
M. Withofs, F. Offner, P. De Paepe and M. Praet

744 **Familial follicular lymphoma: a case report with molecular analysis**
K. W. Last, L. K. Goff, K. E. Summers, M. Neat, M. Jenner, C. Crawley, A. Z. Rohatiner, J. Fitzgibbon and T. A. Lister

745 **Universal leucodepletion to reduce potential risk of transmission of new-variant Creutzfeld–Jacob disease**
M. Turner

747 **Universal leucodepletion and new-variant Creutzfeldt-Jakob disease**
M. Sivakumaran

748 **Expression of cell-associated prion protein on normal human platelets**
R. Starke, E. Cramer and P. Harrison

749 **Expression of cell-associated prion protein on normal human platelets – reply**
G. R. Barclay

751 **Incidence of essential thrombocythaemia in children**
H. Hasle

751 **Some limitations in the detection of residual aneuploid cells with DNA quantification on immunophenotyped cells by flow cytometry**
R. Nowak, U. Oelschlägel, T. Heider, R. Naumann and G. Ehninger

752 **Reply to Novak *et al***
J. Almeida, A. Orfao, M. Ocqueteau, G. Mateo, M. Corral, M. D. Caballero, J. Blade, M. J. Moro, J. Hernandez and J. F. San Miguel
753 **Simple methods of preventing cytotoxic disasters**
G. M. Crotty
754 **Thalidomide therapy in refractory solid tumour patients**
J. Gutheil and D. Finucane
755 **BOOK REVIEWS**

Volume 110, Issue 4, September-II 2000

IMAGES IN HAEMATOLOGY

757 **Osteitis fibrosa cystica generalisata with adult T-cell leukaemia: a case report**
T. Yamaguchi

HISTORICAL REVIEW

758 **The history of blood transfusion**
P. L. F. Giangrande

REVIEWS

768 **Dyskeratosis congenita in all its forms**
I. Dokal
780 **The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia**
E. J. Estlin, M. Ronghe, G. A. A. Burke and S. M. Yule
791 **Classification of *ex vivo* methotrexate resistance in acute lymphoblastic and myeloid leukaemia**
M. G. Rots, R. Pieters, G. J. L. Kaspers, A. J. P. Veerman, G. J. Peters and G. Jansen
801 **Investigation of 9-*O*-acetylated sialoglycoconjugates in childhood acute lymphoblastic leukaemia**
C. Mandal, M. Chatterjee and D. Sinha

HAEMATOLOGICAL MALIGNANCY

813 ***In vitro* drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia**
J. Styczynski, R. Pieters, D. R. Huismans, G. J. Schuurhuis, M. Wysocki and A. J. P. Veerman
819 **Activation of an ataxia telangiectasia mutation-dependent intra-S-phase checkpoint by anti-tumour drugs in HL-60 and human lymphoblastoid cells**
K. Sugimoto, K. Tamayose, M. Takagi, K. Yamada, M. Sasaki, S. Mizutani and K. Oshimi
826 **Detection of different Ikaros isoforms in human leukaemias using real-time quantitative polymerase chain reaction**
S. Olivero, C. Maroc, E. Beillard, J. Gabert, W. Nietfeld, C. Chabannon and C. Tonnelle
831 **T-cell prolymphocytic leukaemia: antigen receptor gene rearrangement and a novel mode of *MTCP1* B1 activation**
P. J. J. C. De Schouwer, M. J. S. Dyer, V. B. Brito-Babapulle, E. Matutes, D. Catovsky and M. R. Yuille

839 **The incidences of trisomy 8, trisomy 9 and D20S108 deletion in polycythaemia vera: an analysis of blood granulocytes using interphase fluorescence *in situ* hybridization**
N. B. Westwood, A. M. Gruszka-Westwood, C. E. Pearson, C. E. M. DeLord, A. R. Green, B. J. P. Huntly, A. Lakhani, M. F. McMullin and T. C. Pearson

847 **Cytogenetic and molecular diagnosis of chromosome 5 deletions in myelodysplasia**
C. A. Westbrook, W.-T. Hsu, B. Chyna, D. Litvak, A. Raza and S. K. Horrigan

856 **Diagnostic utility of fluorescence *in situ* hybridization in mantle-cell lymphoma**
E. D. Remstein, P. J. Kurtin, I. Buño, R. J. Bailey, J. Proffitt, W. A. Wyatt, C. A. Hanson and G. W. Dewald

Short reports

863 **Primary myelosarcomas are associated with a high rate of relapse: report on 34 children from the acute myeloid leukaemia–Berlin–Frankfurt–Münster studies**
D. Reinhardt, A. Pekrun, M. Lakomek, M. Zimmermann, J. Ritter and U. Creutzig

867 **Novel BCR–ABL transcript containing an intronic sequence insert in a patient with Philadelphia-positive acute lymphoblastic leukaemia**
M. Hirota, E. Hidaka, I. Ueno, M. Ishikawa, N. Asano, K. Yamauchi, F. Ishida, M. Tozuka and T. Katsuyama

871 **Acute leukaemia in acromegaly patients**
W. Y. Au, W. S. Chow, K. S. L. Lam, G. T. C. Ko, C. S. Cockram and Y. L. Kwong

874 **Sight-threatening varicella zoster virus infection after fludarabine treatment**
Y. L. Chee, D. J. Culligan, J. A. Olson, P. Molyneaux, J. B. Kurtz and H. G. Watson

876 **Involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence *in situ* hybridization to cells collected by means of fluorescence-activated cell sorting**
I. Miura, Y. Kobayashi, N. Takahashi, K. Saitoh and A. B. Miura

880 **Nephrotic syndrome caused by protein thrombi in glomerulocapillary lumen in Waldenström's macroglobulinaemia**
Y. Harada, N. Ido, T. Okada, M. Otani, T. Shirota, T. Nakao and T. Hayashi

884 **Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis**
M. Aivado, A. Rong, U. Germing, N. Gattermann, G. Kobbe, C. Rieth, R. Haas and C. Aul

TRANSPLANTATION

887 **Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells**
N. C. Gorin, M. Labopin, P. Pichard, J. Sierra, D. Fiere, B. Rio, G. Meloni, M. A. Sanz, A. Iriondo, L. Fouillard and F. Frassoni

894 **Cytomegalovirus colitis after autologous transplantation for multiple myeloma**
D. J. C. Ramsey and S. A. Schey

Short reports

897 **Allogeneic haematopoietic transplantation for Richter's syndrome**
J. Rodriguez, M. J. Keating, S. O'Brien, R. E. Champlin and I. F. Khouri

900 **Two-step immunoablative treatment with autologous peripheral blood CD34$^+$ cell transplantation in an 8-year-old boy with autoimmune haemolytic anaemia**
C. Paillard, J. Kanold, P. Halle, K. Yakouben, N. Boiret, C. Rapatel, M. Berger, G. Malpuech and F. Deméocq

GENE THERAPY

Short report 903 **Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and enhanced green fluorescence protein genes in primary T lymphocytes**
S. Di Florio, C. Sebastiani, M. Fagioli, M. Di Ianni, D. Alfonsi, G. Venditti, P. G. Pelicci and A. Tabilio

PLATELETS, HAEMOSTASIS & THROMBOSIS

907 **Glycoprotein Ib/IX complex is the target in rifampicin-induced immune thrombocytopenia**
J. Pereira, P. Hidalgo, M. Ocqueteau, M. Blacutt, M. Marchesse, Y. Nien, L. Letelier and D. Mezzano

911 **Defective platelet response to arachidonic acid and thromboxane A_2 in subjects with Pl^{A2} polymorphism of β_3 subunit (glycoprotein IIIa)**
G. Andrioli, P. Minuz, P. Solero, S. Pincelli, R. Ortolani, S. Lussignoli and P. Bellavite

919 **Bernard–Soulier syndrome in a patient doubly heterozygous for two frameshift mutations in the glycoprotein Ibα gene**
V. Afshar-Kharghan, F. E. Craig and J. A. López

925 **The central role of the P_{2T} receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity**
R. F. Storey, H. M. Sanderson, A. E. White, J. A. May, K. E. Cameron and S. Heptinstall

935 **Fibrinogen polymorphisms are not associated with the risk of myocardial infarction**
C. J. M. Doggen, R. M. Bertina, V. Manger Cats and F. R. Rosendaal

939 **Factor V Leiden: the venous thrombotic risk in thrombophilic families**
R. Lensen, F. Rosendaal, J. Vandenbroucke and R. Bertina

946 **Haemostatic screening and identification of zebrafish mutants with coagulation pathway defects: an approach to identifying novel haemostatic genes in man**
P. Jagadeeswaran, M. Gregory, S. Johnson and B. Thankavel

957 **Contrasting effects of HSP72 expression on apoptosis in human umbilical vein endothelial cells and an angiogenic cell line, ECV304**
M. Lucas, P. E. Rose and A. G. Morris

Short report 965 **Relationship between bleeding time, aspirin and the PIA1/A2 polymorphism of platelet glycoprotein IIIa**
A. Szczeklik, A. Undas, M. Sanak, M. Frołow and W. Węgrzyn

LEUCOCYTES

SHORT report 968 **Th1 and Th2 cytokines in a patient with Evans' syndrome and profound lymphopenia**
M. Karakantza, A. Mouzaki, M. Theodoropoulou, J. B. Bussel and A. Maniatis

ERYTHROCYTES & IRON

971 **Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major**
P. T. Telfer, E. Prestcott, S. Holden, M. Walker, A. V. Hoffbrand and B. Wonke

978 **Relationship between TNF-α and iron metabolism in differentiating human monocytic THP-1 cells**
A. Scaccabarozzi, P. Arosio, G. Weiss, L. Valenti, P. Dongiovanni, A. L. Fracanzani, M. Mattioli, S. Levi, G. Fiorelli and S. Fargion

985 **Chelator-induced iron excretion in iron-overloaded marmosets**
T. Sergejew, P. Forgiarini and H.-P. Schnebli

993 **A new PKLR gene mutation in the R-type promoter region affects the gene transcription causing pyruvate kinase deficiency**
L. Manco, M. L. Ribeiro, V. Máximo, H. Almeida, A. Costa, O. Freitas, J. Barbot, A. Abade and G. Tamagnini

Short report 998 **Erythrocyte membranes from a patient with congenital dyserythropoietic anaemia type I (CDA-I) show identical, although less pronounced, glycoconjugate abnormalities to those from patients with CDA-II (HEMPAS)**
E. Zdebska, B. Woźniewicz, A. Adamowicz-Salach and J. Kościelak

CORRESPONDENCE

1002 **Childhood essential thrombocythaemia without evidence of myeloproliferation: how many investigations should be done?**
G. C. F. Chan, S. K. Ma, S. Y. Ha, L. C. Chan and Y. L. Lau

1003 **Antenatal testing for haemoglobinopathies**
P. Telfer, B. De la Salle and C. Ridler

1004 **Reply to Telfer *et al***
D. W. Galvani

1004 **Transfection of receptor tyrosine kinase *axl* into human haematopoietic cells does not cause spontaneous cellular aggregation**
M. Schmidt, J. Müller, J. Proba, G. Ehninger and A. Neubauer

1006 **Preretinal neovascularization in south-east Asian ovalocytosis**
A. A. van de Loosdrecht, P. F. H. Franck, V. W. Renardel de Lavalette, J. W. Smit and S. M. G. J. Daenen

1006 **Effect of elite cycling on leucocyte counts**
J. F. Lesesve, M. Guinot, S. Andolfatto, M.-C. Béné and G. Dine

1009 **Essential thrombocythaemia in children: a report of nine cases**
R.-C. Yang and L.-S. Qian

1010 **All-*trans* retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia**
J. E. Brown, A. Olujohungbe, J. Chang, W. D. J. Ryder, G. R. Morganstern, R. Chopra and J. H. Scarffe

1012 **Aggressive multiple modality therapy for varicella-associated purpura fulminans**
D. P Busuttil, C. R. M. Hay, M. A. Lewis and R. F. Wynn

1013 **Rituximab salvage following relapse after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma**
D. Milojkovic, A. Mijovic, C. G. Taylor, G. J. Mufti and A. Pagliuca

1015 AUTHOR AND KEYWORD INDEXES TO VOLUME 110